Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.creatorCosta, Lima S
dc.creatorSilvestre, R
dc.creatorBarros, D
dc.creatorCunha, J
dc.creatorBaltazar, M
dc.creatorDinis-Oliveira, R
dc.creatorCordeiro-da-Silva, A
dc.description.abstractThis work aims to develop poly(d,l-lactide-co-glycolide) (PLGA)-nanospheres containing amphotericin B (AmB) with suitable physicochemical properties and anti-parasitic activity for visceral leishmaniasis (VL) therapy. When compared with unloaded-PLGA-nanospheres, the AmB-loaded PLGA-nanospheres displayed an increased particle size without affecting the polydispersity and its negative surface charge. AmB stability in the PLGA-nanospheres was > 90% over 60-days at 30°C. The AmB-PLGA-nanospheres demonstrated significant in vitro and in vivo efficacy and preferential accumulation in the visceral organs. In addition, an immune-modulatory effect was observed in mice treated with AmB-PLGA-nanospheres, correlating with improved treatment efficacy. The in vitro cytotoxic response of the T-lymphocytes revealed that AmB-PLGA-nanospheres efficacy against VL infection was strictly due to the action of CD8 + - but not CD4 + -T lymphocytes. Overall, we demonstrate a crucial role for CD8 + cytotoxic T lymphocytes in the efficacy of AmB-PLGA nanospheres, which could represent a potent and affordable alternative for VL therapy. From the Clinical Editor: This study demonstrates a crucial role for CD8+ T lymphocytes in eliminating visceral leishmaniasis in a murine model by enhancing the cytotoxic efficacy of CD8+ T-cells via amphotericin-B-PLGA nanospheres, paving a way to a unique, potentially more potent and cost-effective therapeutic strategy.
dc.description.sponsorshipThis work was supported by Fundo Europeu de Desenvolvimento Regional (FEDER) funds through the Operational Competitiveness Program-COMPETE and by national funds through Fundação para a Ciência e a Tecnologia under projects FCOMP-01-0124-FEDER-015718 (PTDC/SAU- ENB/113151/2009) and Fundação Caloust Gulbenkian under project P-105348/2009. D.B. was supported by FCOMP-01-0124-FEDER-015718 (PTDC/SAU-ENB/113151/2009) project. S.A.C.L, J.C. T.B. and R.D-O. were supported by SFRH/BPD/37880/2007, SFRH/BD/48626/2008, SFRH/BD/65387/2009 and IF/01147/2013, respectively. R.S. was supported by Programa Ciência, financed by Programa Operacional Potencial Humano–Quadro de Referência Estratégica Nacional-Tipologia 4.2-Promoção do Emprego Científico, co-funded by Fundo Social Europeu and national funding from the Ministry of Science, Technology and Higher Education.
dc.relation.ispartofNanomedicine: Nanotechnology, Biology, and Medicine, vol.10(5), p. 1021-1030
dc.subject.meshAmphotericin B/chemistry
dc.subject.meshAmphotericin B/therapeutic use
dc.subject.meshAntiprotozoal Agents/chemistry
dc.subject.meshAntiprotozoal Agents/therapeutic use
dc.subject.meshCD8-Positive T-Lymphocytes/metabolism
dc.subject.meshLeishmaniasis, Visceral/drug therapy
dc.subject.meshLeishmaniasis, Visceral/immunology
dc.subject.meshMice, Inbred BALB C
dc.subject.meshT-Lymphocytes, Cytotoxic/metabolism
dc.titleCrucial CD8(+) T-lymphocyte cytotoxic role in amphotericin B nanospheres efficacy against experimental visceral leishmaniasis.
dc.typeArtigo em Revista Científica Internacional
dc.contributor.uportoInstituto de Investigação e Inovação em Saúde
Appears in Collections:I3S - Artigo em Revista Científica Internacional

Files in This Item:
File Description SizeFormat 
Lima2014.pdf995.59 kBAdobe PDFThumbnail

This item is licensed under a Creative Commons License Creative Commons